Suboptimal recognition of a T cell epitope of the major dog allergen Can f 1 by human T cells

Molecular Immunology

Volumn 46, Issue 16, 2009, Pages 3320-3327

  Juntunen, Riikka ^a   Liukko, Aino ^a   Taivainen, Antti ^b   Närvänen, Ale ^a   Durand, Guillaume ^c   Kauppinen, Anu ^a   Nieminen, Anssi ^a   Rytkönen Nissinen, Marja ^a   Saarelainen, Soili ^a   Maillère, Bernard ^c   Virtanen, Tuomas ^a   Kinnunen, Tuure ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

Author keywords

Allergy; Altered peptide ligand; Can f 1; Human leukocyte antigen; T cell receptor

Indexed keywords

ALLERGEN; CAN F 1 PEPTIDE; EPITOPE; GAMMA INTERFERON; HLA DP ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ALLERGENICITY; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BINDING KINETICS; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; LYMPHOCYTE PROLIFERATION; MOLECULAR RECOGNITION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TH2 CELL;

CANIS FAMILIARIS; MAMMALIA;

EID: 70349467752     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2009.07.022     Document Type: Article

References (36)

1. Bellinghausen I., Metz G., Enk A.H., Christmann S., Knop J., and Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur. J. Immunol. 27 (1997) 1131-1139
2. Bielekova B., Sung M.H., Kadom N., Simon R., McFarland H., and Martin R. Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J. Immunol. 172 (2004) 3893-3904
3. Bohle B., Kinaciyan T., Gerstmayr M., Radakovics A., Jahn-Schmid B., and Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J. Allergy Clin. Immunol. 120 (2007) 707-713
4. Brogdon J.L., Leitenberg D., and Bottomly K. The potency of TCR signaling differentially regulates NFATc/p activity and early IL-4 transcription in naive CD4+ T cells. J. Immunol. 168 (2002) 3825-3832
5. Castelli F.A., Buhot C., Sanson A., Zarour H., Pouvelle-Moratille S., Nonn C., Gahery-Segard H., Guillet J.G., Menez A., Georges B., and Maillere B. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J. Immunol. 169 (2002) 6928-6934
6. Ettinger R.A., Liu A.W., Nepom G.T., and Kwok W.W. Exceptional stability of the HLA-DQA1*0102/DQB1*0602 alpha beta protein dimer, the class II MHC molecule associated with protection from insulin-dependent diabetes mellitus. J. Immunol. 161 (1998) 6439-6445
7. Ghaemmaghami A.M., Robins A., Gough L., Sewell H.F., and Shakib F. Human T cell subset commitment determined by the intrinsic property of antigen: the proteolytic activity of the major mite allergen Der p 1 conditions T cells to produce more IL-4 and less IFN-gamma. Eur. J. Immunol. 31 (2001) 1211-1216
8. Hemmer B., Fleckenstein B.T., Vergelli M., Jung G., McFarland H., Martin R., and Wiesmuller K.H. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone. J. Exp. Med. 185 (1997) 1651-1659
9. Hemmer B., Vergelli M., Gran B., Ling N., Conlon P., Pinilla C., Houghten R., McFarland H.F., and Martin R. Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. J. Immunol. 160 (1998) 3631-3636
10. Immonen A., Farci S., Taivainen A., Partanen J., Pouvelle-Moratille S., Narvanen A., Kinnunen T., Saarelainen S., Rytkonen-Nissinen M., Maillere B., and Virtanen T. T cell epitope-containing peptides of the major dog allergen Can f 1 as candidates for allergen immunotherapy. J. Immunol. 175 (2005) 3614-3620
11. Immonen A., Kinnunen T., Sirven P., Taivainen A., Houitte D., Perasaari J., Narvanen A., Saarelainen S., Rytkonen-Nissinen M., Maillere B., and Virtanen T. The major horse allergen Equ c 1 contains one immunodominant region of T cell epitopes. Clin. Exp. Allergy 37 (2007) 939-947
12. Immonen A.K., Taivainen A.H., Narvanen A.T., Kinnunen T.T., Saarelainen S.A., Rytkonen-Nissinen M.A., and Virtanen T.I. Use of multiple peptides containing T cell epitopes is a feasible approach for peptide-based immunotherapy in Can f 1 allergy. Immunology 120 (2007) 38-46
13. Jeal H., Draper A., Harris J., Taylor A.N., Cullinan P., and Jones M. Determination of the T cell epitopes of the lipocalin allergen Rat n 1. Clin. Exp. Allergy 34 (2004) 1919-1925
14. Jutel M., Akdis M., Budak F., Aebischer-Casaulta C., Wrzyszcz M., Blaser K., and Akdis C.A. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. J. Immunol. 33 (2003) 1205-1214
15. Jutel M., Pichler W.J., Skrbic D., Urwyler A., Dahinden C., and Muller U.R. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J. Immunol. 154 (1995) 4187-4194
16. Kinnunen T., Buhot C., Narvanen A., Rytkonen-Nissinen M., Saarelainen S., Pouvelle-Moratille S., Rautiainen J., Taivainen A., Maillere B., Mantyjarvi R., and Virtanen T. The immunodominant epitope of lipocalin allergen Bos d 2 is suboptimal for human T cells. Eur. J. Immunol. 33 (2003) 1717-1726
17. Kinnunen T., Jutila K., Kwok W.W., Rytkonen-Nissinen M., Immonen A., Saarelainen S., Narvanen A., Taivainen A., and Virtanen T. Potential of an altered peptide ligand of lipocalin allergen Bos d 2 for peptide immunotherapy. J. Allergy Clin. Immunol. 119 (2007) 965-972
18. Kinnunen T., Kwok W.W., Narvanen A., Rytkonen-Nissinen M., Immonen A., Saarelainen S., Taivainen A., and Virtanen T. Immunomodulatory potential of heteroclitic analogs of the dominant T-cell epitope of lipocalin allergen Bos d 2 on specific T cells. Int. Immunol. 17 (2005) 1573-1581
19. Kinnunen T., Taivainen A., Partanen J., Immonen A., Saarelainen S., Rytkonen-Nissinen M., Rautiainen J., and Virtanen T. The DR4-DQ8 haplotype and a specific T cell receptor Vbeta T cell subset are associated with absence of allergy to Can f 1. Clin. Exp. Allergy 35 (2005) 797-803
20. Lamhamedi-Cherradi S.E., Martin R.E., Ito T., Kheradmand F., Corry D.B., Liu Y.J., and Moyle M. Fungal proteases induce Th2 polarization through limited dendritic cell maturation and reduced production of IL-12. J. Immunol. 180 (2008) 6000-6009
21. Nembrini C., Abel B., Kopf M., and Marsland B.J. Strong TCR signaling, TLR ligands, and cytokine redundancies ensure robust development of type 1 effector T cells. J. Immunol. 176 (2006) 7180-7188
22. Nicholson L.B., Waldner H., Carrizosa A.M., Sette A., Collins M., and Kuchroo V.K. Heteroclitic proliferative responses and changes in cytokine profile induced by altered peptides: implications for autoimmunity. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 264-269
23. Platts-Mills T.A. The role of indoor allergens in chronic allergic disease. J. Allergy Clin. Immunol. 119 (2007) 297-302
24. Radauer C., Bublin M., Wagner S., Mari A., and Breiteneder H. Allergens are distributed into few protein families and possess a restricted number of biochemical functions. J. Allergy Clin. Immunol. 121 (2008) 847-52.e7
25. Reefer A.J., Carneiro R.M., Custis N.J., Platts-Mills T.A., Sung S.S., Hammer J., and Woodfolk J.A. A role for IL-10-mediated HLA-DR7-restricted T cell-dependent events in development of the modified Th2 response to cat allergen. J. Immunol. 172 (2004) 2763-2772
26. Rogers P.R., and Croft M. Peptide dose, affinity, and time of differentiation can contribute to the Th1/Th2 cytokine balance. J. Immunol. 163 (1999) 1205-1213
27. Saarelainen S., Taivainen A., Rytkonen-Nissinen M., Auriola S., Immonen A., Mantyjarvi R., Rautiainen J., Kinnunen T., and Virtanen T. Assessment of recombinant dog allergens f 1 and Can f 2 for the diagnosis of dog allergy. Clin. Exp. Allergy 34 (2004) 1576-1582
28. Shreffler W.G., Castro R.R., Kucuk Z.Y., Charlop-Powers Z., Grishina G., Yoo S., Burks A.W., and Sampson H.A. The major glycoprotein allergen from Arachis hypogaea, Ara h 1, is a ligand of dendritic cell-specific ICAM-grabbing nonintegrin and acts as a Th2 adjuvant in vitro. J. Immunol. 177 (2006) 3677-3685
29. Singh H., and Raghava G.P. ProPred: prediction of HLA-DR binding sites. Bioinformatics 17 (2001) 1236-1237
30. Texier C., Pouvelle S., Busson M., Herve M., Charron D., Menez A., and Maillere B. HLA-DR restricted peptide candidates for bee venom immunotherapy. J. Immunol. 164 (2000) 3177-3184
31. Texier C., Pouvelle-Moratille S., Busson M., Charron D., Menez A., and Maillere B. Complementarity and redundancy of the binding specificity of HLA-DRB1, -DRB3 -DRB4 and -DRB5 molecules. Eur. J. Immunol. 31 (2001) 1837-1846
32. Traidl-Hoffmann C., Mariani V., Hochrein H., Karg K., Wagner H., Ring J., Mueller M.J., Jakob T., and Behrendt H. Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization. J. Exp. Med. 201 (2005) 627-636
33. Virtanen T., and Kinnunen T. Mammalian allergens. In: Lockey R.F., and Ledford D.K. (Eds). Allergens and Allergen Immunotherapy (2008), Informa Healthcare Inc., New York 201-218
34. Virtanen T., Zeiler T., Rautiainen J., and Mantyjarvi R. Allergy to lipocalins: a consequence of misguided T-cell recognition of self and nonself?. Immunol Today 20 (1999) 398-400
35. Zeiler T., Mantyjarvi R., Rautiainen J., Rytkonen-Nissinen M., Vilja P., Taivainen A., Kauppinen J., and Virtanen T. T cell epitopes of a lipocalin allergen colocalize with the conserved regions of the molecule. J. Immunol. 162 (1999) 1415-1422
36. Zhao Y., Gran B., Pinilla C., Markovic-Plese S., Hemmer B., Tzou A., Whitney L.W., Biddison W.E., Martin R., and Simon R. Combinatorial peptide libraries and biometric score matrices permit the quantitative analysis of specific and degenerate interactions between clonotypic TCR and MHC peptide ligands. J. Immunol. 167 (2001) 2130-2141